{
  "docId": "019de073-42e0-708e-bbdb-4616fa343de3",
  "docSlug": "252a92bcbab8bda657ee7494bf765251",
  "documentTitle": "BioAtla | Investor Presentation Deck | 37 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 37,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 7,
  "notes": "SCCHN = Squamous Cell Carcinoma of the Head and Neck. ROR2 is the target biomarker.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-42e0-708e-bbdb-4616fa343de3/26",
  "deckHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3",
  "deckJsonHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3.json",
  "deckAnchorHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.03,
        "y": 0.75
      },
      "kind": "list",
      "text": "Target population: ~12K ROR2+ addressable 2L+ patients/year in the U.S., based on a ROR2 positivity rate of ~60%\nInternal success threshold: 2L+ ORR of ~15% (approvability bar); 15%+ (commercially relevant) following BA3011 monotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dddc5f44-4ed5-4925-8bd2-c2bf64cf4966",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.33,
        "x": 0.03,
        "y": 0.439
      },
      "kind": "metric",
      "text": "~50% with locally advanced disease develop recurrent or refractory disease",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02a7ca24-309c-478c-afda-e8f44743c022",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.33,
        "x": 0.37,
        "y": 0.184
      },
      "kind": "metric",
      "text": "~66K newly diagnosed cases / year (U.S.)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21e2e0c5-13f6-4e04-8eb4-d51ce2161a7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.33,
        "x": 0.03,
        "y": 0.184
      },
      "kind": "metric",
      "text": ">400K people living with head and neck cancer (U.S.)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "733b658c-a951-4de0-89fd-c36c3a2a75b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.33,
        "x": 0.37,
        "y": 0.439
      },
      "kind": "metric",
      "text": "2L+ limited effective options post IL",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd86e3b4-a435-4f25-8d55-6b200fdd7159",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.23,
        "x": 0.733,
        "y": 0.228
      },
      "kind": "paragraph",
      "text": "Available Treatment: 1L: Pembro, cetuximab, platinum 36% ORR; 2L+: ICIs 13% - 16% ORR",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13a86ef2-a65d-42b1-9d94-6ddfcdc796e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.11,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Clarivate, Disease Landscape and Forecast: SCCHN (2022)...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1411a828-e83d-4b6f-858a-5163be07c89e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Potential market opportunity in SCCHN",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7280783f-3505-4ef8-a210-afc222810368",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "657d360d-a46a-415a-a35b-5fb60484d211",
      "evidence": "list/bullet: Target population: ~12K ROR2+ addressable 2L+ patients/year in the U.S., based on a ROR2 positivity rate of ~60%",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 27,
      "from": 10,
      "beatId": "c5004055-d5ec-4e67-8d3c-a6006b26dc07",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents encouraging Phase 1 and 2 results for various indications, demonstrating traction.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 27,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "70b35119-d82b-4aab-a655-ee1318f5401a",
      "evidence": "The deck presents encouraging Phase 1 and 2 results for various indications, demonstrating potential for quick wins and big bets.",
      "position": 2,
      "objective": "What are the potential quick wins and big bets for BioAtla's CAB technology?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}